Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 12-Week Randomized, Double-Blind, Parallel Group, Placebo-Controlled Dose Range Finding Study to Evaluate the Efficacy of Oglemilast in the Treatment of Stable Mild to Moderate Persistent Asthma.

Next Previous
Search
Trial Profile

A 12-Week Randomized, Double-Blind, Parallel Group, Placebo-Controlled Dose Range Finding Study to Evaluate the Efficacy of Oglemilast in the Treatment of Stable Mild to Moderate Persistent Asthma.

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 12 Dec 2009

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Oglemilast (Primary)
  • Indications Asthma
  • Focus Therapeutic Use

Most Recent Events

  • 25 Sep 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
  • 25 Sep 2009 Planned end date changed from Sep 2009 to Jan 2010 as reported by ClinicalTrials.gov.
  • 10 Mar 2009 Planned number of patients changed from 230 to 282 based on information from ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top